Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PRCP | P42785 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18506018 | 0.93 | SMN1; SMN2 (0.49) | PREPTSHRL3MBTL1NPC1RAB9A | |
| SCHEMBL18506025 | 0.88 | PREP (0.50) | PREPACE2TSHRL3MBTL1KDM4E | |
| SCHEMBL809534 | 0.86 | PREP (0.57) | PREPACE2TSHRL3MBTL1KDM4E | |
| SCHEMBL25678348 | 0.84 | SIGMAR1 (0.52) | PREPACE2NPSR1NPC1RAB9A | |
| SCHEMBL16983239 | 0.84 | PREP (0.55) | PREPACE2TSHRL3MBTL1KDM4E | |
| SCHEMBL7312769 | 0.84 | PREP (0.55) | PREPACE2TSHRL3MBTL1KDM4E | |
| SCHEMBL7318776 | 0.84 | PREP (0.55) | PREPACE2TSHRL3MBTL1KDM4E | |
| SCHEMBL7312764 | 0.84 | PREP (0.55) | PREPACE2TSHRL3MBTL1KDM4E | |
| SCHEMBL13198885 | 0.83 | NPC1 (0.60) | PREPACE2TSHRL3MBTL1KDM4E | |
| SCHEMBL14646609 | 0.83 | NPC1 (0.60) | PREPACE2TSHRL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9682965-B2 | Fumagillol heterocyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682965-B2 | Fumagillol heterocyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170066749-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170066749-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2017027684-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066749-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | PREP 6/4885ACE2 46/4885TSHR 4113/4885 |
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | PREP 6/4885ACE2 46/4885TSHR 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.